#Liver Meeting 2020

People with both obesity and liver steatosis were at greater risk for hospitalization with COVID-19.

Despite limited testing and clinical visits, 95% of the study population was able to achieve a sustained virological response.

The experimental therapy improved liver inflammation, fibrosis and metabolic parameters in six months.

The diabetes medication, alone or in combination regimens, led to improvements in NASH and fibrosis.

The hep C mortality reduction goal will not be met by any state, according to recent projections.

Vitamin B-12 and folate not only lowered homocysteine levels in the blood but also improved liver inflammation in mice.

Researchers suggest that 67.3 million people are living with NAFLD in the United States and Canada.

The incidence rate is expected to be especially high among young women with alcoholic liver disease.

Two different studies found that Vemlidy was safe and effective for pregnant women and their infants.

Regardless of cirrhosis status, Mavyret led to high sustained virologic response rates in Latinos and other groups with hep C.

Despite new guidelines, too few infants born to mothers with hepatitis C were screened for the virus.

Racial differences in waiting list placement improved in states that expanded Medicaid.

Areas with lower population density have not seen the same slowdown as urban areas.

Requiring sobriety prior to treatment and curtailing harm reduction hinder efforts to eliminate hep C.